Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Evoke Pharma (EVOK)

Evoke Pharma (EVOK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,546
  • Shares Outstanding, K 24,703
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,130 K
  • 60-Month Beta 2.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 19.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.28 +81.25%
on 05/11/20
2.79 -16.85%
on 05/26/20
+0.96 (+70.59%)
since 05/01/20
3-Month
0.79 +193.67%
on 03/19/20
2.79 -16.85%
on 05/26/20
+0.94 (+68.12%)
since 03/03/20
52-Week
0.50 +363.91%
on 06/26/19
2.79 -16.85%
on 05/26/20
+1.65 (+246.27%)
since 06/03/19

Most Recent Stories

More News
Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has conditionally...

EVOK : 2.32 (-2.11%)
Thinking about buying stock in Arbutus Biopharma, Dynavax Technologies, Applied DNA Sciences, Evoke Pharma, or Aphria?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABUS, DVAX, APDN, EVOK, and APHA.

APHA : 4.46 (-0.89%)
APDN : 8.36 (-13.28%)
ABUS : 2.06 (-1.44%)
DVAX : 6.86 (-4.46%)
EVOK : 2.32 (-2.11%)
Evoke Pharma Reports First Quarter 2020 Financial Results and Changes its 2020 Annual Meeting of Stockholders to a Virtual Format

Gimoti(TM) Prescription Drug User Fee Act (PDUFA) date is June 19, 2020

EVOK : 2.32 (-2.11%)
Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and full year...

EVOK : 2.32 (-2.11%)
Evoke Pharma Receives Notice of Allowance from USPTO for Gimoti(TM)

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United States Patent and Trademark Office (USPTO)...

EVOK : 2.32 (-2.11%)
Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti(TM)

EVERSANA to commercialize and distribute Gimoti in the U.S.

EVOK : 2.32 (-2.11%)
Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance

The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.

PDLI : 3.19 (-1.54%)
EPZM : 17.43 (-0.17%)
EVOK : 2.32 (-2.11%)
DNLI : 28.82 (+1.44%)
FDA Accepts Evoke Pharma's NDA Resubmission for Gimoti(TM)

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the U.S. Food and Drug...

EVOK : 2.32 (-2.11%)
Evoke Resubmits Gimoti(TM) New Drug Application to FDA

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has resubmitted its 505(b)(2) New Drug Application...

EVOK : 2.32 (-2.11%)
Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 29, 2019, it received notification from...

EVOK : 2.32 (-2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade EVOK with:

Business Summary

Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke...

See More

Key Turning Points

2nd Resistance Point 2.49
1st Resistance Point 2.40
Last Price 2.32
1st Support Level 2.27
2nd Support Level 2.23

See More

52-Week High 2.79
Last Price 2.32
Fibonacci 61.8% 1.92
Fibonacci 50% 1.65
Fibonacci 38.2% 1.37
52-Week Low 0.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar